Actively Recruiting
Evaluating Safety, Tolerability, and Immune Response of FB-102 Given by Injection in Healthy Adults Compared to Placebo
Led by Forte Biosciences, Inc. · Updated on 2026-10-21
64
Participants Needed
2
Research Sites
17 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effects of FB-102 in healthy adult volunteers aged 18 to 60 years in this Phase 1 clinical trial. The study aims to understand how FB-102 behaves in the body and how the immune system responds after single and multiple doses. It compares FB-102 with a placebo under controlled conditions. FB-102 is given in three parts Part A involves a single dose Part B provides weekly doses for four weeks Part C gives doses every two weeks for four doses. Participants may also join an optional extension period lasting about 15 weeks, during which no drug is given but blood samples and safety monitoring continue. Participants will undergo various assessments including blood tests to measure drug levels and immune responses, as well as monitoring for any adverse effects from day 1 through Day 85. Safety, tolerability, and pharmacokinetics are the main focus. The total involvement spans several months, including dosing and follow-up to ensure thorough evaluation of FB-102.
CONDITIONS
Brief Title
A Study Testing the Safety and Effects of FB102 in Healthy Volunteers
Research Team
A
Alistair Mallard
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here